[Therapeutic results with the aromatic retinoid (Tigason) in Sharp syndrome and progressive scleroderma].
As experimental findings indicated inhibitory action of aromatic retinoid on microtubule polymerisation and collagen metabolism of mesenchymal cells, we decided to treat 5 patients suffering from progressive systemic sclerosis as well as 3 patients with Sharp's syndrome with aromatic retinoid (Tigason). All 8 patients of this preliminary study responded positively to this therapy, but there were individual differences. The dosage corresponded to that applied in psoriasis. There were no severe side effects observed. In our opinion, these results justify the application of aromatic retinoid in patients suffering from progressive systemic sclerosis or Sharp's syndrome.
D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy* / Q000503:physiopathology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000503:physiopathology
D005050:Etretinate
Therapeutische Erfolge mit aromatischem Retinoid (Tigason) bei Sharp-Syndrom und progressiver Sklerodermie.